Pilot Study of Hydroxychloroquine for the Treatment of AIMSS

The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase Inhibitor Associated Musculoskeletal Syndrome (AIMSS) for patients with breast cancer.

Trial Details

NCT ID
NCT07825454
Phase
PHASE2
Sponsor
Indiana University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Hydroxychloroquine Sulfate (HCQ)
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

  • Age ≥ 18 years at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization
  • Diagnosis of DCIS or stage I, II, or III breast cancer
  • Currently receiving adjuvant aromatase inhibitor therapy (anastrozole, letrozole or exemestane) for ≥ 4 weeks prior to enrollment Note: Concurrent …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →